Why the study?
Antiplatelet therapy is central to preventing cardiovascular diseases, prompting the need to review the Total Thrombus-Formation Analysis System (T-TAS) alongside conventional systems for evaluating antithrombotic therapies.
Does the Total Thrombus-Formation Analysis System (T-TAS) improve the assessment of thrombus formation and prediction of bleeding events in patients with cardiovascular disease compared to conventional tests?
Does the Total Thrombus-Formation Analysis System (T-TAS) improve the assessment of thrombus formation and prediction of bleeding events in patients with cardiovascular disease compared to conventional tests?
The T-TAS system provides a novel, flow-based methodological approach to comprehensively evaluate the combined effects of antiplatelet and anticoagulant therapies, potentially aiding in bleeding risk stratification.
T-TAS may support assessment of combined antiplatelet effects; leaves open its role in guiding therapy.
Antiplatelet therapy is the mainstay preventive strategy for cardiovascular diseases, and dual antiplatelet therapy comprising aspirin and a P2Y12 inhibitor is the standard treatment for patients who underwent percutaneous coronary intervention. The Total Thrombus‑Formation Analysis System (T‑TAS) is a microchip flow‑chamber system developed to evaluate overall thrombus formation under flow conditions, which is reportedly able to assess single and combined antithrombotic therapy. Here, we focus on this new system, T‑TAS, and review its characteristics together with those of the conventional systems available for evaluation of antithrombotic therapies for cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Hosokawa et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: